While others divest, Sandoz expands: "Antibiotics are the backbone of modern medicine"

Unlike many large pharmaceutical companies, Sandoz is still investing in antibiotics, most recently through the acquisition of a GSK portfolio and an expansion in European production. This business area will remain central to the company, says Carol Lynch.

Photo: Sandoz / PR

The antibiotics business at Sandoz has been on something of a rollercoaster ride over the past two years. After a spike in demand at the start of the pandemic, sales plummeted due to cancelled operations, and the company has only just started to see normalization on the market.

It might therefore seem paradoxical that Sandoz has started two of its biggest projects in years within antibiotics during this period. The first is a significant upgrade to its production facilities in Austria and Spain, and the second is the acquisition of Glaxosmithkline's cefalasporin antibiotic portfolio.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs